Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CDL-H5269 | Human | Human CD40 Ligand / TNFSF5 Protein, Fc Tag (active trimer) (MALS verified) |
![]() ![]() |
![]() ![]() |
|
CDL-H52Db | Human | Human CD40 Ligand / TNFSF5 Protein, His,Flag Tag (active trimer) (MALS verified) |
![]() ![]() |
![]() ![]() |
|
CDL-H82Q8 | Human | Biotinylated Human CD40 Ligand / TNFSF5 Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
CDL-H5256 | Human / Rhesus macaque | Human / Rhesus macaque CD40 Ligand / TNFSF5 Protein, Mouse IgG2a Fc Tag, low endotoxin | ![]() |
![]() ![]() |
![]() ![]() |
CDL-H82F1 | Human | Biotinylated Human CD40 Ligand / TNFSF5 Protein, Avitag™,Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
CDL-H5248 | Human | Human CD40 Ligand / TNFSF5 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
CDL-H5267 | Human | Human CD40 Ligand / TNFSF5 Protein, Fc tag | ![]() |
![]() ![]() |
![]() ![]() |
CDL-M526x | Mouse | Mouse CD40 Ligand / TNFSF5 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
CDL-M5248 | Mouse | Mouse CD40 Ligand / TNFSF5 Protein, His Tag (active trimer) (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
FACS analysis shows that Human CD40 Ligand, Fc Tag (active trimer) (MALS verified) (Cat. No. CDL-H5269) can bind to 293T-CD40 cells surface CD40. The concentration of Human CD40 Ligand is 0.3 μg/mL (Routinely tested).
Loaded Human CD40, Fc Tag (HPLC-verified) (Cat. No. CD0-H5253) on Protein A Biosensor, can bind Human CD40 Ligand, His,Flag Tag (active trimer) (MALS verified) (Cat. No. CDL-H52Db) with an affinity constant of 1.58 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Schönbeck U, Libby P, 2001, Cell. Mol. Life Sci. 58 (1): 4–43.
Furman M.I. et al., 2004, J. Am. Coll. Cardiol. 43: 2319-25.
Banchereau, J. et al., 1994, Annu. Rev. Immunol. 12: 881-922.
Ni, C.Z. et al., 2000, Proc. Natl. Acad. Sci. U.S.A. 97: 10395-10399.
Ferrari.S. et al., 2001, Proc. Natl. Acad. Sci. U.S.A. 98: 12614-12619.
Armitage, R.J. et al., 1993, J Immunol., 150 (9): 3671-3680.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
CD154 gene therapy (Tragen) | Ad-ISF154; ISF-154 | Phase Ⅱ | University of California San Diego, Tragen Pharmaceuticals | Chronic lymphocytic leukemia (CLL) | Details |
MEDI-4920 | MEDI-4920; VIB-4920,MEDI4920; VIB4920 | Phase Ⅱ | MedImmune, Viela Bio | Rejection of renal transplantation | Details |
Toralizumab | IDEC-131; E-6040 | Phase Ⅱ | Seikagaku, Biogen, Eisai | Autoimmune diseases, Psoriasis, Systemic lupus erythematosus, Multiple sclerosis (MS), Rheumatoid arthritis (RA), Idiopathic thrombocytopenic purpura (ITP), Crohn's disease | Details |
Anti-CD40L antibody (Bristol-Myers Squibb) | Phase Ⅱ | Bristol-Myers Squibb | Immunodeficiency disorders | Details | |
INX-021 | INX-021; SAR-441344 | Phase Ⅰ | ImmuNext, Sanofi | Multiple sclerosis (MS) | Details |
ABBV-428 | ABBV-428; ABBV428 | Phase Ⅰ | Abbvie | Solid tumours | Details |
Delolimogene mupadenorepvec | LOAd-703 | Phase Ⅱ | Uppsala University, Lokon Pharma | Colorectal cancer, Ovarian cancer, Pancreatic cancer, Biliary cancer | Details |
Ruplizumab | BG-9588 | Phase Ⅱ | Biogen | Hemophilia A, Autoimmune diseases, Systemic lupus erythematosus, Immune thrombocytopenic purpura, Multiple sclerosis (MS), Rejection of renal transplantation | Details |
BIIB-063 | BIIB-063 | Phase Ⅰ | Biogen | Sjoegren's syndrome | Details |
Dapirolizumab pegol | CDP-7657; Anti-CD40L-Fab; Anti-CD40L-Fab-PEG; CD40L - Fab,CDP7657 | Phase Ⅲ | Biogen, UCB | Systemic lupus erythematosus | Details |
rVV-740CTA vaccine (University Hospital Basel) | rVV-740CTA,rVV 740CTA | Phase Ⅰ | University Hospital Basel | Breast cancer | Details |
SL-172154 | SL-172154 | Phase Ⅰ | Shattuck Labs | Ovarian cancer | Details |
Letolizumab | BMS-986004; BMS2h-572-633-CT-L2 ,BMS986004 | Phase Ⅱ | Bristol-Myers Squibb | Immune thrombocytopenic purpura | Details |
AdCD40L | Phase Ⅱ | Uppsala University | Bladder cancer, Melanoma | Details |
This web search service is supported by Google Inc.